PDCD1 and cancer: This study suggests that the balance of PD-1 expression between CD8+ effector T cells and Tregs in the TME should be considered as a clinically meaningful biomarker to predict the efficacy of PD-1-blocking immunotherapy in various cancers including SCC (Aksoylar and Boussiotis, 2020; Kumagai et al., 2020).